Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy

Prajwal Boddu, Preetesh Jain, Gautam Borthakur, Srdan Verstovsek, Guillermo Garcia-Manero, Naval Daver, Tapan Kadia, Farhad Ravandi, Elias Jabbour, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Considering the risk of arterio-thrombotic adverse events (AEs), ponatinib trials in previously untreated chronic myeloid leukemia chronic phase (CML-CP) were terminated. We conducted a retrospective CML-CP outcome study of patients who discontinued frontline-ponatinib. Among 51 patients who received frontline ponatinib, 38 discontinued because of FDA request and 13 due to AEs. At ponatinib discontinuation, all patients remained in CP with deepest response being CCyR, n = 7; PCyR, n = 4; MMR, n = 14; MR4.5, n = 26. Of the four patients in PCyR at ponatinib discontinuation, two improved response to CCyR on subsequent TKI. Of seven patients, in CCyR at discontinuation, five improved response to MMR or deeper, one was inevaluable, and another lost response due to treatment noncompliance. With a median follow-up of 39 months, 3-year EFS and OS were 92% and 96%, respectively, indicating favorable long-term outcomes. The cardiac/vascular system AEs with subsequent TKI occurred in patients with prior similar events on ponatinib. AEs occurred up to 9 months post-ponatinib.

Original languageEnglish (US)
Pages (from-to)3172-3180
Number of pages9
JournalLeukemia and Lymphoma
Volume60
Issue number13
DOIs
StatePublished - Nov 10 2019
Externally publishedYes

Keywords

  • Ponatinib
  • chronic myeloid leukemia
  • chronic phase
  • frontline
  • outcomes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy'. Together they form a unique fingerprint.

  • Cite this

    Boddu, P., Jain, P., Borthakur, G., Verstovsek, S., Garcia-Manero, G., Daver, N., Kadia, T., Ravandi, F., Jabbour, E., Cortes, J., & Kantarjian, H. (2019). Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leukemia and Lymphoma, 60(13), 3172-3180. https://doi.org/10.1080/10428194.2019.1617862